CD44; HMG-CoA reductase

Class

CD44-targeted active-targeting liposomal nanoparticle delivering rosuvastatin (HMG-CoA reductase inhibitor/statin) directly to atherosclerotic plaque

Pathway

Enhanced cholesterol efflux and anti-inflammatory effects within atherosclerotic plaque, promoting plaque reversal

This mechanism combines two elements: a delivery vehicle and a cholesterol-lowering drug, engineered to act locally within atherosclerotic plaques—the fatty, inflamed lesions that build up in artery walls and underlie heart attack and stroke risk. The vehicle is a liposome, a lipid-based nanoparticle, decorated with a ligand that binds CD44, a cell-surface receptor for hyaluronic acid that becomes highly expressed on activated macrophages, the immune cells that accumulate within plaques and drive their inflammation and instability. This targeting allows the nanoparticle to concentrate in diseased tissue rather than distributing evenly through the body. The payload is rosuvastatin, a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Statins are already used broadly to lower circulating cholesterol, but they also have direct anti-inflammatory and cholesterol-efflux-promoting effects on cells within plaques when delivered there in sufficient concentration. By routing the drug preferentially to plaque macrophages, this approach aims to intensify those local effects—reducing cholesterol accumulation and inflammation within the lesion itself—while potentially requiring less systemic drug exposure than conventional oral statin therapy. This general strategy, targeted nanomedicine, is relevant across cardiovascular disease where plaque stabilization or regression is a therapeutic goal.